Skip to main content

Advertisement

SpringerLink
Log in

Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To study the biological effects of small inhibitory RNA (siRNA) on endometrial carcinoma cells through disrupting the mRNA of Vascular endothelial growth factor (VEGF), and its inhibitory functions on tumor cells’ proliferation.

Methods

The sequence-specific siRNA of VEGF165 and the mock siRNA were designed, they were transfected into the endometrial carcinoma cell line, Ishikawa cells. Total cell RNAs were extracted from the transfected cells. The mRNA levels of VEGF were then analyzed utilizing real-time fluorescence quantitative RT–PCR (FQ-PCR) post-transfection at 12, 24, 48, 72, and 168 h, respectively. Simultaneously its protein levels were also determined by western blot. Cell proliferations were monitored by MTT assay and cytopathological effects (CPE) were determined by Multispect Imaging System.

Result

The mRNA and protein levels of VEGF declined post-transfection at 12, 24, 48, 72 h, respectively, with a maximum decrease post-transfection at 48 h. The proliferation of Ishikawa cells was significantly inhibited in a similar manner during this time window. All the data were repeated at least three independent times and similar results were achieved.

Conclusion

The small siRNA of VEGF165 can effectively down-regulate its target mRNA and protein levels; consequently proliferation of Ishikawa cells was inhibited. The data strongly imply that VEGF may be involved in the genesis of endometrial carcinoma, which provides a new pathway to treat human endometrial caners.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Raymond CS, Zhu L, Vogt TF et al (2010) In vivo analysis of gene knockdown in tetracycline-inducible shRNA mice. Methods Enzymol 477:415–427

    Article  PubMed  CAS  Google Scholar 

  2. Grassmann R, Jeang KT (2008) The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta 1779(11):706–711

    PubMed  CAS  Google Scholar 

  3. Yang H, Zhou H, Feng P et al. (2010) Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 29:92

    Google Scholar 

  4. Whipple C, Korc M (2008) Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg 393(6):901–910

    Article  PubMed  Google Scholar 

  5. Hongying DAI, Ping Zhang, Shuping Zhao et al (2009) Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells. Oncol Rep 21:395–401

    Google Scholar 

  6. Grothey A, Galanis E (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6(9):507–518

    Article  PubMed  CAS  Google Scholar 

  7. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408

    Article  PubMed  CAS  Google Scholar 

  8. Thurston G, Kitajewski J (2008) VEGF and Delta-Notch: interacting signaling pathways in tumor angiogenesis. Br J Cancer 99(8):1204–1209

    Google Scholar 

  9. Hervé MA, Meduri G, Petit FG et al (2006) Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J Endocrinol 188(1):91–99

    Article  PubMed  Google Scholar 

  10. Wang FQ, Barfield E, Dutta S et al (2009) VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 115(3):414–423

    Article  PubMed  CAS  Google Scholar 

  11. Harper SQ, Davidson BL (2005) Plasmid-based RNA interference: construction of small-hairpin RNA expression vectors. Methods Mol Biol 309:219–235

    PubMed  CAS  Google Scholar 

  12. Phalon C, Rao DD, Nemunaitis J (2010) Potential use of RNA interference in cancer therapy. Expert Rev Mol Med. 18:12–26

    Google Scholar 

  13. Zhou J, Gan N, Zhang W et al (2010) Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor. J Obstet Gynaecol Res 36(2):232–238

    Article  PubMed  CAS  Google Scholar 

  14. Zhang L, Yang N, Mohamed-Hadley A et al (2003) Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 303(4):1169–1178

    Article  PubMed  CAS  Google Scholar 

  15. Holen T, Amarzguioui M, Wiiger MT et al (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nuclei Acids Res 30(8):1757–1766

    Article  CAS  Google Scholar 

  16. Wang X, Wang X, Varma RK et al (2009) Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res 37(22):152

    Article  Google Scholar 

  17. Phipps KM, Martinez A, Lu J et al (2004) Small interfering RNA molecules as potential anti-human rhinovirus agents:in vitro potency, specificity, and mechanism. Antivir Res 61(1):49–55

    Article  PubMed  CAS  Google Scholar 

  18. Elbashir SM, Harborth W, Lendeckel W et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498

    Article  PubMed  CAS  Google Scholar 

  19. Filleur S, Courtin A, Ait-Si-Ali S et al (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63(14):3919–3922

    PubMed  CAS  Google Scholar 

  20. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  21. Wright JD, Powell MA, Rader JS et al (2007) Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 27(5B):3525–3528

    PubMed  CAS  Google Scholar 

  22. Wright JD, Viviano D, Powell MA et al (2006) Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 103(2):489–493

    Article  PubMed  CAS  Google Scholar 

  23. Kamat AA, Merritt WM, Coffey D et al (2007) Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13(24):7487–7495

    Article  PubMed  CAS  Google Scholar 

  24. Yin Y, Cao LY, Wu WQ et al (2010) Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol 16(9):1086–1092

    Article  PubMed  CAS  Google Scholar 

  25. Adham SA, Sher I, Coomber BL (2010) Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab Invest 90(5):709–723

    Article  PubMed  CAS  Google Scholar 

  26. Höbel S, Koburger I, John M et al (2010) Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12(3):287–300

    PubMed  Google Scholar 

  27. Raskopf E, Vogt A, Sauerbruch T et al (2008) siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol 49(6):977–984

    Article  PubMed  CAS  Google Scholar 

  28. Ma Z, Chow KM, Yao J et al (2004) Nuclear shuttling of the peptidase nardilysin. Arch Biochem Biophys 422(2):153–160

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported in part by the Grant (Qingdao Municipal Science and Technology Bureau) to SP. Zhao. The authors greatly appreciated the comments of Dr. John Z. Ma (WRIISC, VAMC at DC, George Washington University School of Medicine, Washington DC, USA); We also greatly thank the editing on this manuscript by Mrs. Brenda J. Jasper (M.Ed., PA-C, WRIISC, VAMC at DC, Howard University, Washington DC, USA).

Conflict of interest

This manuscript does not have any conflict with any biological company or government. All the authors agree to give the right to the editor of Archives of Obstetrics and Gynecology to review this manuscript. The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Affiliated Hospital of Qingdao University School of Medicine, Qingdao, 266003, People’s Republic of China

    Shuping Zhao, Dehua Ma, Hongying Dai, Fang Yuan & Zenyan Wang

Authors
  1. Shuping Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dehua Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongying Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fang Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zenyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuping Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, S., Ma, D., Dai, H. et al. Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells. Arch Gynecol Obstet 284, 1533–1541 (2011). https://doi.org/10.1007/s00404-011-1891-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-011-1891-0

Keywords

Search

Navigation